CIAS
NBIX icon

CBIZ Investment Advisory Services’s Neurocrine Biosciences NBIX Stock Holding History

CBIZ Investment Advisory Services’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.58K Hold
12
– – ﹤0.01% 362
2026
Q1 		$1.58K Hold
12
– – ﹤0.01% 362
2025
Q4 		$1.7K Hold
12
– – ﹤0.01% 666
2025
Q3 		$1.69K Sell
12
-88
-88% -$11.9K ﹤0.01% 584
2025
Q2 		$12.6K Hold
100
– – ﹤0.01% 318
2025
Q1 		$11.1K Hold
100
– – ﹤0.01% 302
2024
Q4 		$13.7K Buy
+100
New +$12.4K ﹤0.01% 256

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

CBIZ Investment Advisory Services's NBIX Position: Q2 2026 in Review

CBIZ Investment Advisory Services held its Neurocrine Biosciences (NBIX) position steady in Q2 2026 at 12 shares worth $1.58K. The position accounts for ﹤0.01% of the portfolio, ranked #362.

CBIZ Investment Advisory Services first reported a position in NBIX in Q4 2024 and has held it in 7 quarters since. The position peaked at $13.7K in Q4 2024. 781 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • CBIZ Investment Advisory Services held 12 shares of Neurocrine Biosciences worth $1.58K as of Q2 2026.
  • CBIZ Investment Advisory Services left its Neurocrine Biosciences share count unchanged in Q2 2026.
  • Neurocrine Biosciences made up ﹤0.01% of CBIZ Investment Advisory Services's portfolio in Q2 2026, its #362 holding.
  • CBIZ Investment Advisory Services first reported a position in Neurocrine Biosciences in Q4 2024 and has held it in 7 quarters since.
  • CBIZ Investment Advisory Services's Neurocrine Biosciences position peaked at $13.7K in Q4 2024.
  • 781 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on CBIZ Investment Advisory Services's 13F filing for Q2 2026, filed 13 Aug 2026.